8-K: ImmunityBio Settles Shareholder Derivative Lawsuits

ImmunityBio, Inc. has reached a proposed settlement in consolidated shareholder derivative actions, agreeing to implement significant corporate governance reforms.

Summary

• ImmunityBio, Inc. has reached a proposed settlement in consolidated shareholder derivative actions, including Van Luven v. Soon-Shiong et al., Barbieri v. Soon-Shiong, et al., and Shin v. Soon-Shiong, et al.
• The lawsuits alleged that individual defendants (current and former officers/directors) breached fiduciary duties by failing to oversee Current Good Manufacturing Practices (cGMP) deficiencies at contract manufacturing organizations (CMOs) for Anktiva, leading to the FDA's rejection of Anktiva's Biologics License Application (BLA) in May 2023, and overstating regulatory approval prospects.
• The proposed settlement, preliminarily approved by the U.S. District Court for the Southern District of California on July 29, 2025, requires ImmunityBio to adopt specific corporate governance reforms for at least four years.
• The company expects attorneys' fees, not to exceed $1,400,000, to be funded by its insurance carrier in exchange for a full release and dismissal of the derivative actions.
• A final approval hearing for the settlement is scheduled for November 4, 2025.
• The FDA approved Anktiva with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ on April 22, 2024, following a second BLA submission.

Sentiment

Score: 7

Explanation: The settlement of significant shareholder derivative litigation, coupled with a commitment to implement substantial corporate governance reforms, is a strong positive for the company's stability and future operations, despite stemming from past negative events. It reduces uncertainty and demonstrates a proactive approach to addressing compliance and oversight issues.

Positives

• Resolution of multiple shareholder derivative lawsuits, reducing ongoing litigation risk and associated legal expenses and management distraction.
• Implementation of substantial corporate governance reforms for at least four years, enhancing oversight, compliance, and internal controls.
• The company acknowledges that the settlement and reforms confer “substantial and material benefits” on ImmunityBio and its shareholders.
• Attorneys' fees for the settlement are expected to be funded by the company's insurance carrier, mitigating direct financial impact.
• FDA approval of Anktiva with BCG on April 22, 2024, for bladder cancer, addressing a prior regulatory setback.

Negatives

• Allegations of breach of fiduciary duties, unjust enrichment, and waste of corporate assets against individual defendants.
• Failure to disclose Current Good Manufacturing Practices (cGMP) deficiencies at contract manufacturing organizations (CMOs) for Anktiva.
• FDA rejection of Anktiva's Biologics License Application (BLA) in May 2023 due to cGMP deficiencies.
• Company's stock price declined as a result of the alleged misconduct.
• Incurring attorneys' fees of up to $1,400,000 (expected to be covered by insurance) as part of the settlement.
• Existence of a related federal securities fraud class action lawsuit (In re ImmunityBio, Inc. Securities Litigation, No. 23-cv-01216) that previously settled for $10.5 million.

Risks

• The inherent litigation risk and uncertainty of outcome in shareholder derivative actions, which the settlement aims to mitigate.
• Potential for the settlement not to receive final court approval, leading to a resumption of litigation.
• Ongoing challenges related to maintaining compliance with FDA regulations and Current Good Manufacturing Practices (cGMP) at manufacturing facilities.
• Reputational damage from past allegations of misconduct and misleading statements.

Future Outlook

ImmunityBio will adopt and maintain significant corporate governance reforms for a period of at least four years, including appointing a new independent director by December 31, 2025, enhancing committee charters, and implementing quarterly board discussions on compliance and annual legal department reviews. Mandatory employee training programs focused on compliance and internal controls will also be established.

Management Comments

• Defendants deny any and all allegations of wrongdoing, liability, violations of law, or damages arising out of or related to any of the conduct, statements, acts, or omissions alleged in the Derivative Matters, and maintain that their conduct was at all times proper, in the best interests of ImmunityBio and its shareholders, and in compliance with applicable law.
• Defendants wish to eliminate the uncertainty, distraction, risk, burden, and expense of further litigation, and to permit the operation of ImmunityBio without further distraction and diversion of its Board and personnel with respect to the Derivative Matters.

Industry Context

This settlement highlights the critical importance of robust corporate governance, transparent disclosure, and strict adherence to regulatory compliance, particularly Current Good Manufacturing Practices (cGMP), within the biotechnology and pharmaceutical industries. FDA approvals are pivotal for product commercialization, and any deficiencies in manufacturing or misleading statements can lead to significant legal and financial repercussions, as evidenced by the prior BLA rejection and subsequent litigation. The industry faces constant scrutiny regarding product safety, efficacy, and manufacturing quality.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Consolidated shareholder derivative actions: Van Luven v. Soon-Shiong et al. (Case No. 3:24-cv-02014-GPC-VET), Barbieri v. Soon-Shiong, et al. (Case No. 3:25-cv-00416-AGS-JLB), and Shin v. Soon-Shiong, et al. (Case No. 3:25-cv-00423-JAH-DDL), alleging breach of fiduciary duty, unjust enrichment, waste of corporate assets, and violations of the Securities Exchange Act of 1934.
• These derivative actions are predicated on the same underlying factual allegations as a related federal securities fraud class action lawsuit, In re ImmunityBio, Inc. Securities Litigation, No. 23-cv-01216 (S.D. Cal.), which settled for $10.5 million.
• An unrelated shareholder derivative lawsuit, Carlson v. Soon-Shiong, et al., C.A. No. 2024-1185-JTL, pending in the Delaware Court of Chancery, is explicitly not included in this settlement.

Related Party Transactions

• The company will continue to post its Related Party Transaction Committee Charter on its Investor Relations/Governance Documents website, indicating a formal process for managing such transactions, though no specific related party dealings are detailed as part of this settlement.

Stakeholder Impact

• Shareholders: Benefit from the resolution of significant litigation, which removes uncertainty and potential future liabilities, and from enhanced corporate governance measures designed to improve oversight and compliance.
• Management and Board of Directors: Will experience reduced distraction from ongoing litigation and will operate under clearer, strengthened governance guidelines, potentially improving decision-making and accountability.
• Employees: Will undergo mandatory training programs focused on compliance and internal controls, fostering a stronger culture of adherence to regulatory and ethical standards.
• Insurance Carriers: Are expected to fund the attorneys' fees for the settlement, indicating their role in mitigating the financial impact on the company.

Next Steps

• A final approval hearing for the derivative settlement is scheduled for November 4, 2025.
• The Board is required to appoint one new independent director by December 31, 2025.
• The Disclosure Committee Charter and Audit Committee Charter will be amended within 30 days of final settlement approval.
• Company management will report to the Board at least quarterly concerning FDA regulations, cGMP compliance, and disclosure accuracy.
• The Legal Department will conduct an annual review and report on the effectiveness of the company's FDA compliance policies.
• Mandatory employee training programs on compliance, internal controls, and risk assessment will be established or maintained within 90 days of final settlement approval.
• Shareholders Counsel will file a fee and expense application with the Court.

Key Dates

Recommendation

The settlement of multiple shareholder derivative lawsuits removes a significant legal and financial overhang for ImmunityBio, reducing uncertainty and potential future liabilities. The commitment to implement robust corporate governance reforms, including board refreshment, enhanced committee charters, and comprehensive employee training, signals a proactive approach to addressing past deficiencies related to FDA compliance and manufacturing practices. While the past issues (FDA rejection of Anktiva BLA due to cGMP deficiencies, stock price decline) were negative, the resolution of this litigation and the proactive governance changes are positive steps towards improving operational integrity and investor confidence. However, the company remains a biotechnology firm with inherent R&D and regulatory risks. The settlement is a de-risking event, but does not fundamentally change the core business model or guarantee future success. Therefore, a 'Hold' recommendation is appropriate, reflecting the improved stability and governance, while acknowledging the ongoing risks and the need for sustained operational performance.

Keywords

ImmunityBio, IBRX, Shareholder Derivative Lawsuit, Settlement, Corporate Governance, FDA Compliance, cGMP, Biotechnology, Pharmaceutical, Litigation, Risk Management, Anktiva